Skip to content

Penumbra PEN Current maturities of long-term debt

Current maturities of long-term debt at other companies

Medtronic logo
MedtronicMDT
Boston Scientific logo
Boston ScientificBSX

Other financials

Income statement

See full
Revenue$374.8M+15.6%
Gross profit$253.4M+17.4%
Operating income$38.2M-5.2%
Net income$32.6M-16.9%
EPS (diluted)$0.82-18.0%

Balance sheet

See full
Cash & equivalents$241.3M-35.8%
Total debt$216.2M-2.0%
Total equity$1.5B+21.5%
Total assets$1.9B+19.2%

Cash flow

See full
Operating cash flow$87.0M+77.6%
CapEx$13.7M+1.5%
Free cash flow$73.3M+106%

Valuation

See full
Market cap$12.48B+25.1%
Enterprise value$12.45B+26.8%
P/E72.9×-163×
P/S8.6×+0.5×

Profitability

See full
Gross margin67.4%+3.7pp
Operating margin12.9%+9.8pp
Net margin11.8%+8.4pp
FCF margin14.6%+2.5pp

Returns & leverage

See full
Return on equity12.7%+9.2pp
Debt / equity0.1×0.0×
Current ratio-0.3×

Where this comes from

Reported directly by Penumbra in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: Penumbra’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Penumbra's current maturities of long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Penumbra's current maturities of long-term debt?
Penumbra (PEN) reported current maturities of long-term debt of $2.39M in Q1 2026.
How has Penumbra's current maturities of long-term debt changed year-over-year?
Penumbra's current maturities of long-term debt increased by 4.1% year-over-year, from $2.29M to $2.39M.
What is the long-term trend for Penumbra's current maturities of long-term debt?
Over 5 years (2020 to 2025), Penumbra's current maturities of long-term debt has grown at a 12.4% compound annual growth rate (CAGR), from $1.33M to $2.39M.